免疫检查点抑制剂所致皮肤免疫相关不良反应的研究进展

doi:10.35541/cjd.20201221

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (11): 1026-1030.doi: 10.35541/cjd.20201221

• 综述 • 上一篇

免疫检查点抑制剂所致皮肤免疫相关不良反应的研究进展

邹美熔汪盛

四川大学华西医院皮肤科，成都 610041

收稿日期:2020-12-24 修回日期:2021-08-18 发布日期:2022-11-03
通讯作者: 汪盛 E-mail:wangsheng1892@126.com

Cutaneous immune-related adverse reactions induced by immune checkpoint inhibitors

Zou Meirong, Wang Sheng

Department of Dermatology, West China Hospital, Sichuan University, Chengdu 610041, China

Received:2020-12-24 Revised:2021-08-18 Published:2022-11-03
Contact: Wang Sheng E-mail:wangsheng1892@126.com

摘要/Abstract

摘要： 【摘要】作为一类新型的抗癌药物，免疫检查点抑制剂在被广泛应用于多种肿瘤治疗的同时，也导致许多免疫相关不良反应，其中以皮肤相关不良反应最为常见。皮肤免疫相关不良反应发病早、大多数程度较轻，但也会出现危及生命的情况。本文综述免疫检查点抑制剂所致皮肤免疫相关不良反应的研究进展。

关键词: 药物毒性, CTLA-4抗原, 程序性细胞死亡受体1, 皮肤表现, 免疫检查点抑制剂

Abstract: 【Abstract】 As a new type of anti-cancer drugs, immune checkpoint inhibitors have been widely used for the treatment of various tumors in recent years, but they have also caused a variety of immune-related adverse reactions, among which cutaneous adverse reactions are the most common. The onset of cutaneous adverse reactions was usually early, and most are mild, but some can also be life-threatening. This review summarizes recent advances in cutaneous immune-related adverse reactions induced by immune checkpoint inhibitors.

Key words: Drug toxicity, CTLA-4 antigen, Programmed cell death 1 receptor, Skin manifestations, Immune checkpoint inhibitors

邹美熔汪盛. 免疫检查点抑制剂所致皮肤免疫相关不良反应的研究进展[J]. 中华皮肤科杂志, 2022,55(11):1026-1030. doi:10.35541/cjd.20201221

Zou Meirong, Wang Sheng. Cutaneous immune-related adverse reactions induced by immune checkpoint inhibitors[J]. Chinese Journal of Dermatology, 2022, 55(11): 1026-1030.doi:10.35541/cjd.20201221

参考文献 61

［1］	Schwartz JC, Zhang X, Fedorov AA, et al. Structural basis for co⁃stimulation by the human CTLA⁃4/B7⁃2 complex［J］. Nature, 2001,410（6828）:604⁃608. doi: 10.1038/35069112.
［2］	Thompson JA. New NCCN guidelines: recognition and management of immunotherapy⁃related toxicity［J］. J Natl Compr Canc Netw, 2018,16（5S）:594⁃596. doi: 10.6004/jnccn.2018.0047.
［3］	Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA⁃4 and PD⁃1 receptors inhibit T⁃cell activation by distinct mechanisms［J］. Mol Cell Biol, 2005,25（21）:9543⁃9553. doi: 10.1128/MCB.25.21. 9543⁃9553.2005.
［4］	Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy⁃related toxicities, version 1.2019［J］. J Natl Compr Canc Netw, 2019,17（3）:255⁃289. doi: 10.6004/jnccn.2019. 0013.
［5］	Tang SQ, Tang LL, Mao YP, et al. The pattern of time to onset and resolution of immune⁃related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients［J］. Cancer Res Treat, 2021,53（2）:339⁃354. doi: 10.4143/crt.2020.790.
［6］	Das R, Bar N, Ferreira M, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade［J］. J Clin Invest, 2018,128（2）:715⁃720. doi: 10.1172/JCI96798.
［7］	Postow MA, Sidlow R, Hellmann MD. Immune⁃related adverse events associated with immune checkpoint blockade［J］. N Engl J Med, 2018,378（2）:158⁃168. doi: 10.1056/NEJMra1703481.
［8］	Lim SY, Lee JH, Gide TN, et al. Circulating cytokines predict immune⁃related toxicity in melanoma patients receiving anti⁃PD⁃1⁃based immunotherapy［J］. Clin Cancer Res, 2019,25（5）:1557⁃1563. doi: 10.1158/1078⁃0432.CCR⁃18⁃2795.
［9］	Berner F, Bomze D, Diem S, et al. Association of checkpoint inhibitor⁃induced toxic effects with shared cancer and tissue antigens in non⁃small cell lung cancer［J］. JAMA Oncol, 2019,5（7）:1043⁃1047. doi: 10.1001/jamaoncol.2019.0402.
［10］	National Cancer Institute, National Institutes of Health. Common terminology criteria for adverse events （CTCAE） v5.0［EB/OL］. ［2020⁃12⁃25］. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
［11］	Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma［J］. N Engl J Med, 2015,372（26）:2521⁃2532. doi: 10.1056/NEJMoa1503093.
［12］	Minkis K, Garden BC, Wu S, et al. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta⁃analysis［J］. J Am Acad Dermatol, 2013,69（3）:e121⁃e128. doi:10.1016/j.jaad.2012.12.963.
［13］	乔瑞, 姜祎群. 常见分子靶向抗肿瘤药物皮肤不良反应及诊治的研究进展［J/OL］.中国皮肤性病学杂志, 2020（2020⁃11⁃16）［2020⁃12⁃25 ］. doi: 10.13735/j.cjdv.1001⁃7089.202006008.
［14］	Donaldson M, Owen JL, Chae YK, et al. Management of persistent pruritus and lichenoid reaction secondary to nivolumab with narrowband ultraviolet B phototherapy［J］. Front Oncol, 2018,8:405. doi: 10.3389/fonc.2018.00405.
［15］	Freeman⁃Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune⁃related adverse events and association with outcomes［J］. Clin Cancer Res, 2016,22（4）:886⁃894. doi: 10.1158/1078⁃0432.CCR⁃15⁃1136.
［16］	Liu RC, Consuegra G, Chou S, et al. Vitiligo⁃like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers［J］. Clin Exp Dermatol, 2019,44（6）:643⁃646. doi: 10.1111/ced.13867.
［17］	Uenami T, Hosono Y, Ishijima M, et al. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report［J］. Lung Cancer, 2017,109:42⁃44. doi: 10.1016/j.lungcan.2017.04. 019.
［18］	Larsabal M, Marti A, Jacquemin C, et al. Vitiligo⁃like lesions occurring in patients receiving anti⁃programmed cell death⁃1 therapies are clinically and biologically distinct from vitiligo［J］. J Am Acad Dermatol, 2017,76（5）:863⁃870. doi: 10.1016/j.jaad. 2016.10.044.
［19］	Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy［J］. J Cutan Pathol, 2017,44（2）:158⁃176. doi: 10.1111/cup.12858.
［20］	斯晓燕, 何春霞, 张丽, 等. 免疫检查点抑制剂相关皮肤不良反应诊治建议［J］. 中国肺癌杂志, 2019,22（10）:639⁃644. doi: 10.3779/j.issn.1009⁃3419.2019.10.06.
［21］	Shi VJ, Rodic N, Gettinger S, et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti⁃programmed cell death 1 and anti⁃programmed cell death ligand 1 immunotherapy［J］. JAMA Dermatol, 2016,152（10）:1128⁃1136. doi: 10.1001/jamadermatol.2016.2226.
［22］	Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor⁃related dermatologic adverse events［J］. J Am Acad Dermatol, 2020,83（5）:1255⁃1268. doi: 10.1016/j.jaad.2020.03. 132.
［23］	Di Altobrando A, Bruni F, Alessandrini A, et al. Severe de⁃novo palmoplantar and nail psoriasis complicating Nivolumab treatment for metastatic melanoma［J］. Dermatol Ther, 2020,33（3）:e13363. doi: 10.1111/dth.13363.
［24］	Bonigen J, Raynaud⁃Donzel C, Hureaux J, et al. Anti⁃PD1⁃induced psoriasis: a study of 21 patients［J］. J Eur Acad Dermatol Venereol, 2017,31（5）:e254⁃e257. doi: 10.1111/jdv. 14011.
［25］	Fattore D, Annunziata MC, Panariello L, et al. Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast［J］. Eur J Cancer, 2019,110:107⁃109. doi: 10. 1016/j.ejca.2019.01.010.
［26］	Johnson D, Patel AB, Uemura MI, et al. IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy［J］. Cancer Immunol Res, 2019,7（6）:860⁃865. doi: 10.1158/2326⁃6066.CIR⁃18⁃0682.
［27］	Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti⁃PD⁃1 and anti⁃PD⁃L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy［J］. J Am Acad Dermatol, 2018,79（6）:1081⁃1088. doi: 10.1016/j.jaad.2018.07. 008.
［28］	Hanley T, Papa S, Saha M. Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma［J］. JRSM Open, 2018,9（10）:2054 270418793029. doi: 10.1177/20542704 18793029.
［29］	Kuwatsuka Y, Iwanaga A, Kuwatsuka S, et al. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab［J］. J Dermatol, 2018,45（1）:e21⁃e22. doi: 10.1111/1346⁃8138.14043.
［30］	Okada H, Kamiya K, Murata S, et al. Case of lichen planus pemphigoides after pembrolizumab therapy for advanced urothelial carcinoma［J］. J Dermatol, 2020,47（9）:e321⁃e322. doi: 10. 1111/1346⁃8138.15461.
［31］	McNally MA, Vangipuram R, Campbell MT, et al. Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma［J］. JAAD Case Rep,2021,10:82⁃84. doi:10.1016/j.jdcr.2021.02.012.
［32］	张悦昕，陈喜雪. 发生于特瑞普利单抗长期治疗后的大疱性类天疱疮二例［J］. 中华皮肤科杂志, 2021, 54（2）: 131⁃135.doi: 10.35541/cjd.20200483.
［33］	Chen WS, Tetzlaff MT, Diwan H, et al. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: a spectrum of immune reactions from paraneoplastic pemphigus⁃like to Grover⁃like lesions［J］. J Cutan Pathol, 2018,45（10）:764⁃773. doi: 10.1111/cup.13312.
［34］	Ridpath AV, Rzepka PV, Shearer SM, et al. Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab⁃induced bullous pemphigoid［J］. Int J Dermatol, 2018,57（11）:1372⁃1374. doi: 10.1111/ijd.13970.
［35］	Damsky W, Jilaveanu L, Turner N, et al. B cell depletion or absence does not impede anti⁃tumor activity of PD⁃1 inhibitors［J］. J Immunother Cancer, 2019,7（1）:153. doi: 10.1186/s40425⁃019⁃0613⁃1.
［36］	Sowerby L, Dewan AK, Granter S, et al. Rituximab treatment of nivolumab⁃induced bullous pemphigoid［J］. JAMA Dermatol, 2017,153（6）:603⁃605. doi: 10.1001/jamadermatol.2017.0091.
［37］	Kremer N, Snast I, Cohen ES, et al. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature［J］. Am J Clin Dermatol, 2019,20（2）:209⁃216. doi: 10.1007/s40257⁃018⁃0401⁃6.
［38］	Wang F, Qin S, Sun X, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial［J］. J Hematol Oncol, 2020,13（1）:47. doi: 10.1186/s13045⁃020⁃00886⁃2.
［39］	秦叔逵, 马军, 李进, 等. 卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识［J］. 临床肿瘤学杂志, 2020,25（09）:840⁃848.
［40］	位变, 王华庆, 柳凤亭, 等. PD⁃1抑制剂卡瑞利珠单抗治疗恶性肿瘤引发反应性皮肤毛细血管增生二例［J］. 中华皮肤科杂志, 2021,54（03）:252⁃253. doi: 10.35541/cjd.20190821.
［41］	Galli G, Proto C, Cossa M, et al. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non⁃small cell lung cancer［J］. Tumori,2019,105（6）:NP57⁃NP62. doi: 10.1177/0300891619872546.
［42］	Kuntz T, Koushk⁃Jalali B, Kreuter A. Sunitinib⁃induced pyoderma gangrenosum⁃like skin ulcer［J］. CMAJ, 2020,192（20）:E552. doi: 10.1503/cmaj.191165.
［43］	Yaşar HA, Akkus E, Heper A, et al. Sweet′s syndrome under ipilimumab therapy and a brief comparison of the cases in literature［J］. J Oncol Pharm Pract, 2020,26（7）:1762⁃1764. doi:10.1177/1078155220906885.
［44］	Salamaliki C, Solomou EE, Liossis SC. Immune checkpoint inhibitor⁃associated scleroderma⁃like syndrome: a report of a pembrolizumab⁃induced "eosinophilic fasciitis⁃like" case and a review of the literature［J］. Rheumatol Ther, 2020,7（4）:1045⁃1052. doi: 10.1007/s40744⁃020⁃00246⁃z.
［45］	Zitouni NB, Arnault JP, Dadban A, et al. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review［J］. Melanoma Res, 2019,29（2）:212⁃215. doi: 10.1097/CMR.0000000000000536.
［46］	Kosche C, Stout M, Sosman J, et al. Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature［J］. Melanoma Res, 2020,30（3）:313⁃316. doi: 10.1097/CMR.0000000000000642.
［47］	Wiggins CJ, Chon SY. Anti⁃CTLA⁃4 therapy⁃associated granuloma annulare in chronic myelomonocytic leukemia［J］. Proc （Bayl Univ Med Cent）, 2020,34（1）:122⁃123. doi: 10.1080/08998280.2020.1818165.
［48］	Page B, Borradori L, Beltraminelli H, et al. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab［J］. J Eur Acad Dermatol Venereol, 2018,32（7）:e256⁃256e257. doi: 10.1111/jdv.14282.
［49］	Matsubara T, Uchi H, Haratake N, et al. Acute generalized exanthematous pustulosis caused by the combination of pembrolizumab plus chemotherapy in a patient with squamous⁃cell carcinoma［J］. Clin Lung Cancer, 2020,21（2）:e54⁃54e56. doi: 10.1016/j.cllc.2019.11.009.
［50］	Maloney NJ, Ravi V, Cheng K, et al. Stevens⁃Johnson syndrome and toxic epidermal necrolysis⁃like reactions to checkpoint inhibitors: a systematic review［J］. Int J Dermatol, 2020,59（6）:e183⁃183e188. doi: 10.1111/ijd.14811.
［51］	Ibraheim H, Perucha E, Powell N. Pathology of immune⁃mediated tissue lesions following treatment with immune checkpoint inhibitors［J］. Rheumatology （Oxford）, 2019,58（Suppl 7）:vii17⁃17vii28. doi: 10.1093/rheumatology/kez465.
［52］	Dasanu CA. Late⁃onset Stevens⁃Johnson syndrome due to nivolumab use for hepatocellular carcinoma［J］. J Oncol Pharm Pract, 2019,25（8）:2052⁃2055. doi: 10.1177/1078155219830166.
［53］	孔英琪, 陈浩. 新型药物的皮肤不良反应［J/OL］. 中国皮肤性病学杂志, 2020（2020⁃11⁃16）［2020⁃12⁃25］. doi: 10.13735/j.cjdv.1001⁃7089.202007104.
［54］	Gopee NH, Gourley AM, Oliphant TJ, et al. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors［J/OL］. Dermatol Online J, 2020,26（8）. doi:10.5070/D3268049884.
［55］	Coleman EL, Olamiju B, Leventhal JS. The life⁃threatening eruptions of immune checkpoint inhibitor therapy［J］. Clin Dermatol, 2020,38（1）:94⁃104. doi: 10.1016/j.clindermatol.2019. 10.015.
［56］	Mirza S, Hill E, Ludlow SP, et al. Checkpoint inhibitor⁃associated drug reaction with eosinophilia and systemic symptom syndrome［J］. Melanoma Res, 2017,27（3）:271⁃273. doi: 10.1097/CMR.0000000000000326.
［57］	Teulings HE, Limpens J, Jansen SN, et al. Vitiligo⁃like depigmentation in patients with stage III⁃IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta⁃analysis［J］. J Clin Oncol, 2015,33（7）:773⁃781. doi: 10.1200/JCO.2014.57.4756.
［58］	Nakamura Y, Teramoto Y, Asami Y, et al. Nivolumab therapy for treatment⁃related vitiligo in a patient with relapsed metastatic melanoma［J］. JAMA Dermatol, 2017,153（9）:942⁃944. doi: 10. 1001/jamadermatol.2017.1679.
［59］	Lopez AT, Geskin L. A case of nivolumab⁃induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein⁃1/programmed death ligand⁃1 inhibitors and recommendations for diagnosis and management［J］. Oncologist, 2018,23（10）:1119⁃1126. doi: 10.1634/theoncologist. 2018⁃0128.
［60］	Min Lee CK, Li S, Tran DC, et al. Characterization of dermatitis after PD⁃1/PD⁃L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case⁃control study［J］. J Am Acad Dermatol, 2018,79（6）:1047⁃1052. doi: 10.1016/j.jaad.2018. 05.035.
［61］	Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of readministration of immune checkpoint inhibitors after immune⁃related adverse events in patients with cancer［J］. JAMA Oncol, 2019,5（9）:1310⁃1317. doi: 10.1001/jamaoncol.2019.1022.

[1]	顾安康张宇马法库孔祥君张理涛. 游泳池肉芽肿56例临床病理分析[J]. 中华皮肤科杂志, 2022, 55(9): 795-798.
[2]	陈文静邵睿邹云敏孟中勤严翘宋琳毅孙建方陈浩. 黏液表皮样癌8例临床及病理分析[J]. 中华皮肤科杂志, 2022, 55(8): 665-668.
[3]	王媛李志量李锁荆可孙超梁桂熔张寒梅冯素英. 抗p200类天疱疮7例临床及免疫血清学特征分析[J]. 中华皮肤科杂志, 2022, 55(7): 557-561.
[4]	高子蕊赵培窦沅青刘萍张建中. 度普利尤单抗治疗成人结节性痒疹的疗效与安全性观察[J]. 中华皮肤科杂志, 2022, 55(7): 562-565.
[5]	施雁庭黎皓郑捷曹华. 程序性细胞死亡蛋白1及其配体通路在特发性炎症性肌病中的研究进展[J]. 中华皮肤科杂志, 2022, 55(7): 633-636.
[6]	张宁李舒李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 55(7): 603-609.
[7]	张诗敏胡赟赟赵肖庆杜联军曹华郑捷. 影像技术在皮肌炎诊断和病情评估中的研究进展[J]. 中华皮肤科杂志, 2022, 55(7): 637-640.
[8]	黄馨陈筱昀李亚萍梁兴堃张桂英周英湛意罗帅寒天廖洁月肖嵘龙海. 度普利尤单抗治疗123例特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022, 55(6): 486-493.
[9]	申晨陈俊均杨骥胡东艳辛崇美李明. 硬斑病患者180例临床特征及分类探讨[J]. 中华皮肤科杂志, 2022, 55(4): 308-315.
[10]	刘擘宋晓婷李若瑜赵作涛. 【开放获取】度普利尤单抗治疗特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022, 55(4): 295-298.
[11]	王晓雯李若瑜. 白细胞介素17相关生物制剂治疗银屑病过程中浅部真菌感染的发生及应对策略[J]. 中华皮肤科杂志, 2022, 55(3): 272-275.
[12]	王召阳陈安薇向欣罗晓燕徐子刚王华马琳. 基于两家儿童医院信息系统的儿童银屑病现状调查[J]. 中华皮肤科杂志, 2022, 55(3): 246-250.
[13]	李浩, 王俐韩宪伟孙彤苏芳孙晓冬韩莹杨国玲刘晓明王凯波 . 糖尿病患者服用二肽基肽酶Ⅳ抑制剂后发生大疱性类天疱疮32例临床特征分析[J]. 中华皮肤科杂志, 2022, 55(3): 213-218.
[14]	韩晓锋孙娟邱磊尉莉马琳. 儿童穿通型毛母质瘤29例临床病理特点分析[J]. 中华皮肤科杂志, 2022, 55(3): 196-199.
[15]	王玥严煜林. 寻常型银屑病患者171例阿维A治疗相关不良反应及停药原因分析[J]. 中华皮肤科杂志, 2022, 55(3): 242-245.

免疫检查点抑制剂所致皮肤免疫相关不良反应的研究进展

Cutaneous immune-related adverse reactions induced by immune checkpoint inhibitors

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 61

相关文章 15

Metrics

本文评价

推荐阅读 10